

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

**Recommended Cash Tender Offer for MedImmune by
AstraZeneca**

Pursuant to the merger agreement with MedImmune, Inc. announced on 23 April, AstraZeneca PLC announces that its wholly-owned subsidiary, AstraZeneca Biopharmaceuticals Inc., today commenced a cash tender offer to acquire all outstanding shares of MedImmune's common stock, par value \$0.01 per share, at a price of \$58.00 per share. The tender offer is scheduled to expire at 12:00 Midnight, New York City time, on Thursday, May 31, 2007, unless extended. Details of the tender offer are contained in the documents that are being sent to MedImmune stockholders and will be posted on astrazeneca.com.

-Ends-

3 May 2007

**AstraZeneca
Media Enquiries**

Steve Brown / Edel McCaffrey (London)	(020) 7304 5033/5034
Staffan Ternby (Sweden)	(8) 553 26107
Emily Denney (Wilmington)	(302) 885 3451

Analyst / Investor Enquiries

Jonathan Hunt /Mina Blair / Karl Hård (London)	(020) 7304 5087/5084/5322
Staffan Ternby (Sweden)	(8) 553 26107
Ed Seage / Jorgen Winroth (US)	(302) 886 4065/ (212) 579 0506

Merrill Lynch (Financial Adviser to AstraZeneca)

Richard Girling	(0) 20 7628 1000
-----------------	------------------

Deutsche Bank (Joint Corporate Broker to AstraZeneca)

Charlie Foreman	(0) 20 7545 8000
-----------------	------------------

Goldman Sachs (Joint Corporate Broker to AstraZeneca)

Phil Raper	(0) 20 7774 1000
------------	------------------